Headquartered in Cranbury, NJ·Fiscal year ends December·NASDAQ: RCKT·rocketpharma.com
About Rocket Pharmaceuticals
Rocket Pharmaceuticals is a commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases. Its strategic focus is inherited cardiovascular disorders, and it also has programs in hematology and immunology.
Its cardiovascular portfolio includes three clinical-stage AAV gene therapy programs:
- RP-A501 for Danon disease, a hypertrophic cardiomyopathy, now in a pivotal Phase 2 trial.
- RP-A601 for PKP2 arrhythmogenic cardiomyopathy, in Phase 1.
- RP-A701 for BAG3-associated dilated cardiomyopathy, in Phase 1.
The company has proprietary AAV manufacturing capabilities and clinical experience in cardiac gene therapy.
Its first commercial product is KRESLADI (marnetegragene autotemcel). It is an autologous, lentiviral-vector hematopoietic stem cell gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), approved under accelerated approval. KRESLADI reached commercial readiness on October 1, 2026, with two Qualified Treatment Centers activated and an external manufacturing network in place.
The company funds development through cash and investments, proceeds from a priority review voucher sale, and a credit facility of up to $150 million with Hercules Capital. Updated
Pre-Market Stock Futures: Futures are trading higher as the Federal Reserve’s reckoning day has arrived. Interest rate futures tracked by CME FedWatch show a 92% chance of a 25-basis-point increase in the…
Tuesday’s additional top analyst upgrades and downgrades were on Ballard Power Systems, Block, Dave & Buster’s Entertainment, DigitalOcean, Lyft, Six Flags Entertainment, SolarEdge Technologies, William-Sonoma and more.
Rocket Pharmaceuticals is a commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases. Its strategic focus is inherited cardiovascular disorders, and it also has programs in hematology and immunology.
What is the RCKT stock price target?
The Wall Street consensus 12-month price target for RCKT is $8.82.